{"id":"fosfomycin-sodium-intravenous","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2322189","moleculeType":"Small molecule","molecularWeight":"160.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosfomycin is a broad-spectrum antibiotic that acts as a phosphoenolpyruvate (PEP) analogue, irreversibly inhibiting UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), a key enzyme in bacterial peptidoglycan biosynthesis. This disruption of cell wall formation leads to bacterial cell lysis and death. The intravenous sodium formulation allows systemic delivery for treatment of serious infections.","oneSentence":"Fosfomycin inhibits bacterial cell wall synthesis by inactivating the MurA enzyme, preventing peptidoglycan cross-linking.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:19.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections caused by susceptible pathogens"},{"name":"Multidrug-resistant gram-negative infections"}]},"trialDetails":[{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT06570850","phase":"PHASE4","title":"Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection","status":"RECRUITING","sponsor":"Chiang Mai University","startDate":"2023-04-01","conditions":"Infection Due to Carbapenem Resistant Acinetobacter","enrollment":188},{"nctId":"NCT03910673","phase":"PHASE1","title":"Intravenous Fosfomycin Pharmacokinetics Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-27","conditions":"Bacterial Infection, Multiple-drug Resistance, Pathogen Resistance","enrollment":39},{"nctId":"NCT03709914","phase":"PHASE1","title":"PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)","status":"UNKNOWN","sponsor":"Nabriva Therapeutics AG","startDate":"2018-05-24","conditions":"Pediatric ALL","enrollment":21},{"nctId":"NCT02142751","phase":"PHASE3","title":"Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2014-07","conditions":"Infection Due to ESBL Escherichia Coli","enrollment":161},{"nctId":"NCT03709927","phase":"PHASE1","title":"4-way Crossover QT Evaluation in Healthy Subjects","status":"COMPLETED","sponsor":"Nabriva Therapeutics AG","startDate":"2018-01-11","conditions":"Cardiac Repolarization in Healthy Subjects","enrollment":41},{"nctId":"NCT03235947","phase":"PHASE4","title":"Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2016-09-07","conditions":"Urinary Tract Infection, Asymptomatic Bacteriuria","enrollment":82},{"nctId":"NCT02178254","phase":"PHASE1","title":"Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-08","conditions":"Pseudomonas Infection","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Generic name: Fosfomycin","Pharmaceutical form: solution for infusion","ATC code: J01J3"],"phase":"phase_3","status":"active","brandName":"Fosfomycin sodium intravenous","genericName":"Fosfomycin sodium intravenous","companyName":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","companyId":"fundaci-n-p-blica-andaluza-para-la-gesti-n-de-la-investigaci-n-en-sevilla","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosfomycin inhibits bacterial cell wall synthesis by inactivating the MurA enzyme, preventing peptidoglycan cross-linking. Used for Serious bacterial infections caused by susceptible pathogens, Multidrug-resistant gram-negative infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}